<DOC>
	<DOC>NCT01633372</DOC>
	<brief_summary>This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).</brief_summary>
	<brief_title>An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>Must be diagnosed with PMF, PPVMF or PETMF as confirmed by bone marrow biopsy. Must score at least 1 point on the Dynamic International Prognostic Scoring System (DIPSS) for prognostic risk factors and have peripheral blast count &lt;10% at both Screening and Baseline hematology assessments. Subjects must discontinue all drugs used to treat underlying MF disease no later than Day 14. Subjects must have hemoglobin value &gt;/= 8.0g/dL and be willing to receive blood transfusions, have a platelet count &gt;/=50x10^9/L and absolute neutrophil count (ANC) &gt;/= 1x10^9/L. Subjects must have palpable spleen or history of splenectomy Active symptoms at the screening visit Women who are pregnant or breastfeeding, and men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively. Subjects with impaired liver function, end stage renal disease on dialysis or clinically significant concurrent infections requiring therapy. Subjects with unstable cardiac function or invasive malignancies over the previous 2 years except treated basal or squamous carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix and completely resected papillary thyroid and follicular thyroid cancers.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>Post Polycythemia Vera Fibrosis</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>Post Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>PET-MF</keyword>
</DOC>